Alarm lateral flow immunoassay for detection of the total infection caused by the five viruses

Safenkova, Irina V.; Panferov, Vasily G.; Panferova, Natalia A.; Varitsev, Yuri A.; Zherdev, Anatoly V.; Dzantiev, Boris B.

doi:10.1016/j.talanta.2018.12.004

Cited by 22 publications

(22 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the decades of application, these test systems have passed the test of time and confirmed their wide availability, high speed of detection, ease of operation and readout of results, and efficient and reliable diagnosis of diseases [21] , [23] – [25] . The cost efficiency and easy-to-handle property of these portable diagnostic systems are fully consistent with the world's modern concept of ‘point-of-care testing’ (laboratory testing at the site of treatment).…”

Section: Lfia-platforms: Types and Formatsmentioning

confidence: 99%

Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19

2020

View full text Add to dashboard Cite

Technologies based on lateral flow immunoassay (LFIA), known in some countries of the world as immunochromatographic tests, have been successfully used for the last six decades in diagnostics of many diseases and conditions as they allow rapid detection of molecular ligands in biosubstrates. The popularity of these diagnostic platforms is constantly increasing in healthcare facilities, particularly those facing limited budgets and time, as well as in household use for individual health monitoring. The advantages of these low-cost devices over modern laboratory-based analyzers come from their availability, opportunity of rapid detection, and ease of use. The attractiveness of these portable diagnostic tools is associated primarily with their high analytical sensitivity and specificity, as well as with the easy visual readout of results. These qualities explain the growing popularity of LFIA in developing countries, when applied at small hospitals, in emergency situations where screening and monitoring health condition is crucially important, and as well as for self-testing of patients. These tools have passed the test of time, and now LFIA test systems are fully consistent with the world's modern concept of ‘point-of-care testing’, finding a wide range of applications not only in human medicine, but also in ecology, veterinary medicine, and agriculture. The extensive opportunities provided by LFIA contribute to the continuous development and improvement of this technology and to the creation of new-generation formats. This review will highlight the modern principles of design of the most widely used formats of test-systems for clinical laboratory diagnostics, summarize the main advantages and disadvantages of the method, as well as the current achievements and prospects of the LFIA technology. The latest innovations are aimed at improving the analytical performance of LFIA platforms for the diagnosis of bacterial and viral infections, including COVID-19.

show abstract

Section: Lfia-platforms: Types and Formatsmentioning

confidence: 99%

Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19

2020

View full text Add to dashboard Cite

show abstract

“…Among precursors of modern biosensor technologies are such diagnostic platforms as quantitative and semi-quantitative test systems for identifying specific antigens [9] and antibodies [10] as well as gene amplification products [11][12][13][14] based on latex agglutination and lateral flow immunoassay (LFIA). In the past decades, these tools have been successfully used to diagnose and identify molecular markers of infection, and they have not lost their biomedical significance today [10,11,13,15] (Figure 1).…”

Section: Lateral Flow Immunoassay (Lfia) As Simplified Formats Of Modmentioning

confidence: 99%

“…When the analyte content in the solution is low, the specimen needs to be concentrated. [14] [ 17,21] [ 15,19] [ 16,18,20] [ [18][19][20] [ 16,18,20] [13] [14,16,17] [18] [13,15,16] [ 18,19] Research and development of these highly selective analytical devices have become a popular and most actively developing biotechnological trend over the past 15-20 years. On the example of biosensors, the technological evolution in the field of measuring devices from semi-quantitative of the immunoassay methods to high-performance modern multifunctional analyzers is especially pronounced [21,22].…”

Section: Possibility Of Multiplexed Formats Of Test Systemsmentioning

confidence: 99%

“…It is interesting that the evolution of sensory technologies developed in parallel with the emergence of diagnostic platforms for the lateral flow immunoassay (LFIA), which in our time are considered as simplified formats of modern biosensors [10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

“…The emergence and use of biosensors based on integrative constructive strategies has enabled these devices in recent decades to be widely used in various fields of science, medicine, pharmacology, biological and food safety, and environmental protection. This biotechnological breakthrough was the result of the development and creation of powerful and sensitive analytical tools that use biological molecular elements as sensors [11,13,18].…”

Section: Introduction To Biosensor Technologiesmentioning

confidence: 99%

See 2 more Smart Citations

Label-Free Biosensors for Laboratory-Based Diagnostics of Infections: Current Achievements and New Trends

et al. 2020

View full text Add to dashboard Cite

Infections pose a serious global public health problem and are a major cause of premature mortality worldwide. One of the most challenging objectives faced by modern medicine is timely and accurate laboratory-based diagnostics of infectious diseases. Being a key factor of timely initiation and success of treatment, it may potentially provide reduction in incidence of a disease, as well as prevent outbreak and spread of dangerous epidemics. The traditional methods of laboratory-based diagnostics of infectious diseases are quite time- and labor-consuming, require expensive equipment and qualified personnel, which restricts their use in case of limited resources. Over the past six decades, diagnostic technologies based on lateral flow immunoassay (LFIA) have been and remain true alternatives to modern laboratory analyzers and have been successfully used to quickly detect molecular ligands in biosubstrates to diagnose many infectious diseases and septic conditions. These devices are considered as simplified formats of modern biosensors. Recent advances in the development of label-free biosensor technologies have made them promising diagnostic tools that combine rapid pathogen indication, simplicity, user-friendliness, operational efficiency, accuracy, and cost effectiveness, with a trend towards creation of portable platforms. These qualities exceed the generally accepted standards of microbiological and immunological diagnostics and open up a broad range of applications of these analytical systems in clinical practice immediately at the site of medical care (point-of-care concept, POC). A great variety of modern nanoarchitectonics of biosensors are based on the use of a broad range of analytical and constructive strategies and identification of various regulatory and functional molecular markers associated with infectious bacterial pathogens. Resolution of the existing biosensing issues will provide rapid development of diagnostic biotechnologies.

show abstract

Nanoparticle‐Based Bioaffinity Assays: From the Research Laboratory to the Market

Farka,

Brandmeier,

Mickert

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Advances in the development of new biorecognition elements, nanoparticle‐based labels as well as instrumentation have inspired the design of new bioaffinity assays. This review critically discusses the potential of nanoparticles to replace current enzymatic or molecular labels in immunoassays and other bioaffinity assays. Successful implementations of nanoparticles in commercial assays and the need for rapid tests incorporating nanoparticles in different roles such as capture support, signal generation elements, and signal amplification systems are highlighted. The limited number of nanoparticles applied in current commercial assays can be explained by challenges associated with the analysis of real samples (e.g., blood, urine, or nasal swabs) that are difficult to resolve, particularly if the same performance can be achieved more easily by conventional labels. Lateral flow assays that are based on the visual detection of the red‐colored line formed by colloidal gold are a notable exception, exemplified by SARS‐CoV‐2 rapid antigen tests that have moved from initial laboratory testing to widespread market adaption in less than two years.

show abstract

Alarm lateral flow immunoassay for detection of the total infection caused by the five viruses

Cited by 22 publications

References 32 publications

Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19

Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19

Label-Free Biosensors for Laboratory-Based Diagnostics of Infections: Current Achievements and New Trends

Nanoparticle‐Based Bioaffinity Assays: From the Research Laboratory to the Market

Contact Info

Product

Resources

About